C
이뮨온시아
424870KOSDAQ40.5 / 100
Reference Date: 2026-09-08
Financial Score15.0 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 8.9% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Imunovia specializes in developing antibody-based immunotherapy drugs, with key assets including Anti-PD-L1, Anti-CD47, and Anti-LAG-3 monoclonal antibodies. The company is conducting Phase 2 trials for IMC-001 in NK/T cell lymphoma and TMB-High solid tumors, aiming for domestic commercialization and the development of a global blockbuster drug.
Number of Employees
22people
Average Salary
103.5M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
9.35Industry Average 1.200.0Point
7.8x industry avg (risky)
ROE
-114.40Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
1.66Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 3.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
0.0 / 4
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (3%, downtrend)
Current 2,910Won52-week high 15,38052-week low 2,445
1-month return1.0Point
1m -8.92% (falling)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral반기보고서 (2026.06)2026-08-14